An Oct. 26 article, Biogen Idec Results Disappoint , contained errors. The article incorrectly stated that Biogen Idec (BIIB:Nasdaq) expects to submit a supplemental application to the Food and Drug Administration by mid-2006 for Tysabri. In fact, the company has already submitted the application and expects a decision from the FDA by mid-2006. The article also incorrectly stated that during the last quarter, Phase II clinical trials studying Tysabri against rheumatoid arthritis were ended. In fact, the rheumatoid arthritis trials were stopped when Tysabri was taken off the market in February. The company said last quarter that data from the suspended trials showed that Tysabri's amount of activity against rheumatoid arthritis didn't warrant continued development for that indication. TheStreet.com regrets the errors. (Corrected Oct. 27)

An Oct. 21 column, What a Week: Wild Ride incorrectly stated that the Nasdaq Composite had lost 22 points, or 1%, in the week ended Oct. 21. In fact, the Nasdaq rose 17 points, or 0.8%, during that period. TheStreet.com regrets the error. ( Corrected Oct. 24.)

An Oct. 14 story, "Refco Unfurling White Flag," incorrectly said some of the historical obligations transferred in the Refco (RFX:NYSE) scandal may have been debts owed by a hedge fund run by Victor Niederhoffer. In fact, sources said, the obligations could have been trading losses incurred by Refco in conjunction with the collapse of Niederhoffer's fund in 1997. The story also incorrectly said Niederhoffer said in 1999 that he would use any award in a lawsuit against the Chicago Mercantile Exchange to pay down substantial losses suffered by him and Refco on Oct. 27, 1997, and on Aug. 13, 1988. In fact, the suit said only that the fund and Refco had suffered substantial losses on and after Oct. 27, 1997. TheStreet.com regrets the error. ( Corrected Oct. 14)

Due to an editing error, an Oct. 12 answer to a radio listener question by James J. Cramer, published in RealMoney Radio: Wal-Mart Works Here , incorrectly stated that Cramer believes Corning (GLW:NYSE) will be part of the tech rally. TheStreet.com regrets the error. (Corrected Oct. 13)

An Oct. 11 column by Howard Simons, Fed, Europe Should Get in Sync on Rates , contained an incorrect chart under the headline "Short-Term Rates And Relative Stock Performance." The corrected chart appears below.

Also, the following sentence: "The returns for American investors in European markets have slid in recent months on both an adjusted and an unadjusted basis, even as the rate gap between the dollar and the euro grew," should have said: "The relative returns to American investors in European markets have advanced in recent months on both an adjusted and an unadjusted basis even as the rate gap between the dollar and the euro grew." TheStreet.com regrets the errors. ( Corrected Oct. 11).

Short-Term Rates And Relative Stock Performance

Source: Bloomberg

An Oct. 11 column by James J. Cramer, Best Play on Japan: Mitsubishi UFJ , incorrectly stated that Mitsubishi UFJ had 248 branches. The bank has 528 branches. TheStreet.com regrets the error. (Corrected Oct. 11)

An Oct. 10 column by James J. Cramer, Bankruptcy Makes Too Much Sense , incorrectly indicated that Yahoo! (YHOO:Nasdaq) was not a member of the S&P 500 index. It is; the column should have indicated that Google (GOOG:Nasdaq) was not included in the benchmark index. TheStreet.com regrets the error. (Corrected Oct. 10)

An Oct. 8 column, JBL: The Ultimate Equity Tag-Team , incorrectly reported that Cisco Systems (CSCO: Nasdaq) has more than $19 billion in cash and investments. In fact, Cisco had over $16 billion in cash and investments as of July 30. TheStreet.com regrets the error. (Corrected Oct. 10)

An Oct. 4 story, Navigating Book-Value Traps," incorrectly said Knight Capital (NITE:Nasdaq) had generated $138 million in cash from operating activities through the first half of 2005. In fact, Knight's cash flow from operations was negative. TheStreet.com regrets the error. (Corrected Oct. 7)

Regulators are asking for more time to review Celgene's Revlimid safety program before deciding whether to approve the blood cancer drug. TheStreet.com regrets the error. (Corrected Oct. 4)

An Oct. 3 column, Gazing Out Into Uncertain Skies , incorrectly stated that FedEx (FDX:NYSE) has lowered its earnings guidance.

FedEx raised its full-year 2006 guidance when it posted fiscal first-quarter earnings on Sept. 21. The company subsequently did warn of an "impact to earnings" from Hurricane Katrina in the second quarter in a regulatory filing on Sept. 23, but it did not quantify the impact. TheStreet.com regrets the error. (Corrected Oct. 3)